Skip to main content
. 2016 Dec 19;7:614. doi: 10.3389/fimmu.2016.00614

Figure 1.

Figure 1

In vitro toll-like receptor (TLR) challenge on PBMCs: CD4 and CD8 T-cell activation, proliferation, and apoptosis. Data shown as a fold change: (stimulated percentage value)/(unstimulated percentage value). *indicates which comparison is the most significant (A) No upregulation of HLA-DR on CD4 T-cells in all the three study groups following TLR challenge [lipopolysaccharide (LPS) p = 0.754; lipoteichoic acid (LTA) p = 0.945; peptidoglycan (PGN) p = 0.739; ssRNA p = 0.623; IFNγ p = 0.396; aCD3/CD28 p < 0.0001]. (B) Significant increase of CD38 + CD8 T-cell upon viral challenge alone in combination antiretroviral therapy group (LPS p = 0.081; LTA p = 0.587; PGN p = 0.360; ssRNA p = 0.044; IFNγ p = 0.764; aCD3/CD28 p = 0.304). (C,D) No differences in the proportion of Ki67 + CD4 T-cells (LPS p = 0.193; LTA p = 0.083; PGN p = 0.149; ssRNA p = 0.358; IFNγ p = 0.762; aCD3/CD28 p = 0.024) and Ki67 + CD8 T-cells following the exposure to TLR ligands (LPS p = 0.609; LTA p = 0.549; PGN p = 0.317; ssRNA p = 0.237; IFNγ p = 0.507; aCD3/CD28 p = 0.069). (E,F) No changes in pro-apoptotic Annexin V + CD4 (LPS p = 0.268; LTA p = 0.638; PGN p = 0.672; ssRNA p = 0.685; IFNγ p = 0.491; aCD3/CD28 p = 0.672) and CD8 (LPS p = 0.606; LTA p = 0.503; PGN p = 0.149; ssRNA p = 0.335; IFNγ p = 0.251; aCD3/CD28 p = 0.038) T-cells.